Enable AccessibilityEnable Accessibility

Shire Named Company Of The Year At Mediscience Awards

June 28, 2010

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company was named Company of the Year in the European Mediscience Awards 2010.

All quoted European mediscience companies are eligible for the European Mediscience Awards, provided that the majority of the business of the company, and its subsidiaries are in the healthcare, medical, pharmaceutical, biotechnology or life sciences sectors. This numbers over 150 quoted companies.

The award scheme recognises the importance of the capital markets to fund growth and innovation in the biopharmaceutical marketplace.  The criteria for the Company of the Year award is a well defined strategy and demonstration of the ability to deliver its key financial, ethical and social ambitions.

Says Angus Russell, Chief Executive Officer of Shire:  “We’re delighted to have been voted Company of the Year at the Mediscience Awards.  This award recognises the success of our strategy and the hard work of everyone at Shire who is so dedicated to meeting the needs of the patients and their families that rely on Shire medicines.”

On behalf of the voting panel, Kate Silverton, BBC personality and Awards presenter, said: “Shire has enjoyed a spectacular year, successfully making an excellent transition from a focus on attention deficit hyperactivity disorders to a genetic disease and specialist biopharmaceutical company.  In financial terms its 25% increase in 2009 in core product sales underlines its potential in 2010 and beyond.” 

For further information please contact:

Jessica Mann +44 1256 894 280
[email protected]

Notes to editors

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

techMARK mediscience
techMARK mediscience is London's international market for healthcare companies.  The market includes all London-listed companies from the biotechnology, specialist pharmaceuticals, diagnostics, drug delivery and medical technology industries.